N@N

Raghuram Selvaraju Reiterated (BBIO) at Strong Buy and Held Target at $43 on, May 30th, 2024

Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BridgeBio Pharma, Inc." (BBIO) at Strong Buy and Held Target at $43 on, May 30th, 2024.

Raghuram has made no other calls on BBIO in the last 4 months.

There are 7 other peers that have a rating on BBIO. Out of the 7 peers that are also analyzing BBIO, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024

These are the ratings of the 6 analyists that currently disagree with Raghuram

---

• Eliana Merle of "UBS" Maintained at Strong Buy with Decreased Target to $47 on, Tuesday, May 28th, 2024
• Josh Schimmer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $70 on, Tuesday, May 28th, 2024
• Cory Kasimov of "Evercore ISI Group" Initiated at Buy and Held Target at $50 on, Tuesday, May 14th, 2024
• Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $45 on, Wednesday, March 20th, 2024
• Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $53 on, Tuesday, March 5th, 2024
• David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024

Contributing Sources

---